Jill Lacy, MD
Medical Oncology · New Haven, CTNPI 1053392951
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,774 of the $39,972 with a category attached, or 87.0%. 9 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 24.2% of the total.
Across 39 payments — averaging $1024.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$10K
- Novartis$7K
- Merck$7K
- AstraZeneca$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Beigene USA, Inc.$3K
- plus $4K from 3 others
Across 463 payments — averaging $7520.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.1M
- Roche Products Limited$759K
- E.r. Squibb & Sons, L.L.C.$467K
- Genmab A/s$409K
- Eli Lilly$250K
- Seagen Inc.$110K
- plus $417K from 11 others
What the payments were for
- Consulting fees$34,77487%
- Speaking & faculty fees$2,6107%
- Travel & lodging$1,6384%
- Food & beverage$9492%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 8 | $9,657 |
| Novartis | 2 | $7,188 |
| Merck | 7 | $6,583 |
| AstraZeneca | 6 | $5,214 |
| E.r. Squibb & Sons, L.L.C. | 9 | $4,249 |
| Beigene USA, Inc. | 3 | $3,398 |
| Genentech, Inc. | 1 | $2,340 |
| Deciphera Pharmaceuticals Inc. | 2 | $1,050 |
| Novocure Inc. | 1 | $293 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,972 in reported general payments places this provider in the 75th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $12,854 |
| ZenpepLipase/Protease/Amylase | 14 | $11,563 |
| Ondansetron OdtOndansetron | 88 | $2,569 |
| Imatinib Mesylate | 21 | $1,359 |
| Dexamethasone | 62 | $1,029 |
| LoperamideLoperamide Hcl | 81 | $600 |
| Prochlorperazine Maleate | 18 | $228 |
| Pantoprazole Sodium | 16 | $198 |
| Oxycodone Hcl | 18 | $182 |
| Famotidine | 12 | $126 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Lajos PusztaiNew Haven$152K
- Howard HochsterNew Haven$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.